Safety Information

metaformin safety

Wegovy is a prescription medication containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is specifically indicated for chronic weight management in adults with obesity or overweight who have at least one weight-related comorbid condition. Wegovy works by mimicking the action of a natural hormone called GLP-1, which helps regulate appetite and food intake. By activating GLP-1 receptors in the brain, Wegovy helps to reduce hunger and promote feelings of fullness, leading to weight loss. It is administered once weekly by subcutaneous injection and is typically used in conjunction with a reduced-calorie diet and increased physical activity.

As with any medication, it’s important to be aware of the potential risks and benefits associated with Wegovy and to use it under the guidance of a qualified healthcare provider. Regular monitoring and communication with your healthcare provider can help ensure the safe and effective use of compounded medications in your treatment regimen.

What is Wegovy Used For?

Wegovy is prescribed to help individuals with obesity (BMI of 30 kg/m² or greater) or overweight (BMI of 27 kg/m² or greater) who have at least one weight-related medical condition such as hypertension, type 2 diabetes mellitus, or dyslipidemia. It is used to reduce excess body weight and sustain weight loss over the long term when combined with a reduced-calorie diet and increased physical activity.

Additionally, Wegovy is indicated to lower the risk of major adverse cardiovascular events (such as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with known cardiovascular disease who are either obese or overweight.

Warning: Risk of Thyroid C-Cell Tumors

Wegovy carries a warning regarding the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). While the absolute risk of MTC with Wegovy is low, healthcare providers should carefully consider this risk before prescribing Wegovy, particularly in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Any unusual symptoms such as a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath should be promptly reported to a healthcare provider, as they may be indicative of thyroid cancer.

Who Should Not Take Wegovy?

Wegovy is contraindicated in certain individuals due to potential risks or medical conditions. Here’s a breakdown of who should not use Wegovy:

  • Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not use Wegovy.
  • Individuals with serious hypersensitivity reactions to semaglutide or any of its components should avoid its use.
  • Pregnant or breastfeeding women should consult their healthcare provider before using Wegovy.

How Should Wegovy be Administered?

Patients should receive proper training on the injection technique from their healthcare provider. It’s important to follow the dosing instructions provided by the healthcare provider and adhere to the recommended injection sites to ensure proper administration of Wegovy.

  • Wegovy is typically administered once weekly by subcutaneous injection. 
  • The injection can be given into the thigh, abdomen, or upper arm.

Foods to Avoid While Taking Wegovy

While taking Wegovy, it’s important to be mindful of certain dietary considerations to optimize its effectiveness and minimize potential side effects. Here are some foods to avoid while taking Wegovy:

High-fat meals

Consuming meals high in fat content may delay the absorption of Wegovy and increase the risk of gastrointestinal side effects such as nausea and diarrhea. Opt for healthier, lower-fat meal options to minimize these effects.

Excessive alcohol consumption

Drinking excessive amounts of alcohol while taking Wegovy may increase the risk of hypoglycemia (low blood sugar). Limit alcohol intake and monitor blood sugar levels closely to avoid complications.

Common Side Effects of Wegovy

  • Nausea
  • Diarrhea
  • Vomiting
  • Abdominal pain
  • Headache
  • Fatigue
  • Dyspepsia (indigestion)
  • Dizziness
  • Abdominal distension
  • Eructation (burping)
  • Flatulence

Most Serious Side Effects of Wegovy

These serious side effects may occur with Wegovy. You or a caregiver must diligently monitor for these potential adverse reactions, especially when starting treatment or adjusting doses.

Thyroid C-Cell Tumors:
Wegovy carries a warning regarding the potential risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). While the absolute risk is low, individuals with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2) should avoid Wegovy.

Inflammation of Pancreas (Acute Pancreatitis):
Patients should be monitored for signs of acute pancreatitis, such as severe abdominal pain that persists, often radiating to the back, with or without vomiting.

Acute Gallbladder Disease:
Wegovy may increase the risk of gallbladder problems, including the formation of gallstones. Symptoms may include upper stomach pain, jaundice (yellowing of the skin or eyes), fever, or pale-colored stools.

Low Blood Sugar (Hypoglycemia):
Wegovy can lower blood sugar levels, potentially leading to hypoglycemia in individuals with type 2 diabetes who are also taking other glucose-lowering medications.

Acute Kidney Injury:
Dehydration due to gastrointestinal side effects associated with Wegovy use may exacerbate kidney problems. Adequate fluid intake is important to reduce the risk of dehydration.

Serious Allergic Reactions:
Discontinue Wegovy immediately if symptoms of a severe allergic reaction occur, such as swelling of the face, lips, tongue, or throat; severe rash or itching; rapid heartbeat; difficulty breathing or swallowing; or fainting.

Diabetic Retinopathy Complications:
Individuals with type 2 diabetes should promptly report any changes in vision to their healthcare provider.

Increase in Heart Rate:
Notify your healthcare provider if you experience a rapid heartbeat while at rest.

Suicidal Behavior and Ideation:
Monitor for changes in mood, behavior, thoughts, or feelings, and promptly report any concerning mental health changes to your healthcare provider.


Please note that these warnings serve to highlight specific risks associated with Wegovy and are not comprehensive. Healthcare providers should review the full prescribing information for Wegovy and consider individual patient factors before prescribing this medication. Patients should consult their healthcare provider for personalized guidance and recommendations regarding the use of Wegovy and the management of any potential risks.